Repositioning Candidate Details
| Candidate ID: | R0099 |
| Source ID: | DB00368 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Norepinephrine |
| Synonyms: | |
| Molecular Formula: | C8H11NO3 |
| SMILES: | NC[C@H](O)C1=CC(O)=C(O)C=C1 |
| Structure: |
|
| DrugBank Description: | Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic. |
| CAS Number: | 51-41-2 |
| Molecular Weight: | 169.1778 |
| DrugBank Indication: | Mainly used to treat patients in vasodilatory shock states such as septic shock and neurogenic shock and has shown a survival benefit over dopamine. Also used as a vasopressor medication for patients with critical hypotension. |
| DrugBank Pharmacology: | Noradrenaline acts on both alpha-1 and alpha-2 adrenergic receptors to cause vasoconstriction. Its effect in-vitro is often limited to the increasing of blood pressure through antagonising alpha-1 and alpha-2 receptors and causing a resultant increase in systemic vascular resistance. |
| DrugBank MoA: | Norepinephrine functions as a peripheral vasoconstrictor by acting on alpha-adrenergic receptors. It is also an inotropic stimulator of the heart and dilator of coronary arteries as a result of it's activity at the beta-adrenergic receptors. |
| Targets: | Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; Alpha-1D adrenergic receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor; Beta-3 adrenergic receptor; Phenylalanine-4-hydroxylase; Synaptic vesicular amine transporter; Chromaffin granule amine transporter |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T03 | Angiotensin-converting enzyme | ACE | INHIBITOR | Target is a single protein chain | P12821 | ACE_HUMAN | Details |
| T06 | Sulfonylurea receptor 1 | ABCC8 | Target is a single protein chain | Q09428 | ABCC8_HUMAN | Details | |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I02 | 1184 | nephrotic syndrome | "A nephrosis characterized by marked increase in glomerular protein permeability resulting in marked elevation of urine protein levels, hypoalbuminemia, hyperlipidemia, and hypercoagulability." [url:https\://en.wikipedia.org/wiki/Nephrotic_syndrome, url:https\://www.niddk.nih.gov/health-information/kidney-disease/nephrotic-syndrome-adults] | Details |